References:
- Adams H.P.Jr. (2009) Secondary prevention of atherothrombotic events after ischemic stroke. Mayo Clin. Proc., 84(1): 43–51. doi: 10.1016/S0025-6196(11)60807-0.
- Albizzati M.G., Bassi S., Binda G., Passerini D. (1980) Effects of vincamine on EEG sleep patterns in man: a pilot study. Curr. Med. Res. Opin., 6(10): 653–657.
- Bagoly E., Fehér G., Szapáry L. (2007) The role of vinpocetine in the treatment of cerebrovascular diseases based in human studies. Orv. Hetil., 148(29): 1353–1358. doi: 10.1556/OH.2007.28115.
- Chiu P.J., Tetzloff G., Ahn H.S., Sybertz E.J. (1988) Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta. Am. J. Hypertens., 1(3 Pt. 1): 262–268. doi: 10.1093/ajh/1.3.262.
- Debette S., Schilling S., Duperron M.G. et al. (2019) Clinical significance of magnetic resonance imaging markers of vascular brain injury: a systematic review and meta-analysis. JAMA Neurol., 76(1): 81–94. doi: 10.1001/jamaneurol.2018.3122.
- Depresseux J.C. (1978) The effect of vincamine on the regional cerebral blood flow in man. Eur. Neurol., 17(2): 100–107.
- Feigin V.L., Doronin B.M., Popova T.F. et al. (2001) Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur. J. Neurol., 8(1): 81–85.
- Go A.S., Mozaffarian D., Roger V.L. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2013) Heart disease and stroke statistics — 2013 update: a report from the American Heart Association. Circulation, 127(1): e6–e245. doi: 10.1161/CIR.0b013e31828124ad.
- Gulyás B., Halldin C., Sóvágó J. et al. (2002) Drug distribution in man: a positron emission tomography study after oral administration of the labelled neuroprotective drug vinpocetine. Eur. J. Nucl. Med. Mol. Imaging, 29(8): 1031–1038. doi: 10.1007/s00259-002-0823-4.
- Horváth S. (2001) The use of vinpocetine in chronic disorders caused by cerebral hypoperfusion. Orv. Hetil., 142(8): 383–389.
- Jeon K.I., Xu X., Aizawa T. et al. (2010) Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc. Natl. Acad. Sci. USA, 107(21): 9795–9800. doi: 10.1073/pnas.0914414107.
- Jincai W., Tingfang D., Yongheng Z. et al. (2014) Effects of vinpocetine and ozagrel on behavioral recovery of rats after global brain ischemia. J. Clin. Neurosci., 21(4): 661–663. doi: 10.1016/j.jocn.2013.07.039.
- Lin C., Chen F., Ye T. et al. (2014) A novel oral delivery system consisting in «drug-in cyclodextrin-in nanostructured lipid carriers» for poorly water-soluble drug: vinpocetine. Int. J. Pharm., 465(1–2): 90–96. doi: 10.1016/j.ijpharm.2014.02.013.
- Medina A.E. (2010) Vinpocetine as a potent antiinflammatory agent. Proc. Natl. Acad. Sci. USA, 107(22): 9921–9922. doi: 10.1073/pnas.1005138107.
- Medina A.E. (2011) Therapeutic utility of phosphodiesterase type I inhibitors in neurological conditions. Front. Neurosci., 5: 21. doi: 10.3389/fnins.2011.00021.
- Ning M., Zhou Y., Chen G., Mei X. (2011) Preparation and in vitro/in vivo evaluation of vinpocetine elementary osmotic pump system. Adv. Pharmacol. Sci., 2011: 385469. doi: 10.1155/2011/385469.
- Olpe H.R., Steinmann M.W. (1982) The effect of vincamine, hydergine and piracetam on the firing rate of locus coeruleus neurons. J. Neural. Transm., 55(2): 101–109.
- Sharma S., Deshmukh R. (2015) Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats. Neuroscience, 286: 393–403. doi: 10.1016/j.neuroscience.2014.12.008.
- Sitges M., Galvan E., Nekrassov V. (2005) Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem. Int., 46: 533–540.
- Subhan Z., Hindmarch I. (1985) Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur. J. Clin. Pharmacol., 28(5): 567–571. doi: 10.1007/bf00544068.
- Szatmari S.Z., Whitehouse P.J. (2003) Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst. Rev., 1: CD003119.
- Vitolo O.V., Sant’Angelo A., Costanzo V. et al. (2002) Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. USA, 99(20): 13217–13221. doi: 10.1073/pnas.172504199.
- World Health Organization (2018) The top 10 causes of death (https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death/).
- Zhang W., Huang Y., Li Y. et al. (2016) Efficacy and safety of vinpocetine as part of treatment for acute cerebral infarction: a randomized, open-label, controlled, multicenter CAVIN (Chinese Assessment for Vinpocetine in Neurology) trial. Clin. Drug Investig., 36(9): 697–704. doi: 10.1007/s40261-016-0415-x.